CVS Health adds Teresa Heitsenrether to its board amid turnaround push

As seen on the 24/7 Wall St. homepage on November 18, 2026.

Now director at CVS HEALTH Corp

Another seat changes hands at CVS Health as the board keeps reshaping around its turnaround, with Glenview Capital already holding four seats after its activist push. Heitsenrether's financial-services background points to tighter capital discipline at a company carrying a $104.1 billion market cap and PBM reform pressure. Watch who else joins before the next proxy.

Continue ReadingShow less

Teresa Heitsenrether joins CVS Health as a director, adding a financial-services background to a board that has been undergoing significant reconstruction. The appointment follows an activist push by Glenview Capital, which already holds four board seats, making this latest addition another visible sign that the reshaping of CVS governance is still in progress.

Heitsenrether's experience in financial services carries a specific relevance here. CVS is a company carrying a $104.1 billion market cap while navigating real pressure on its pharmacy benefit management business, and tighter capital discipline is exactly the kind of focus a board in turnaround mode tends to prioritize.

Sponsored

The Glenview Capital presence looms large over how any new director is read by the market. With four seats already secured by the activist investor, each additional appointment is scrutinized for whether it signals alignment with Glenview's agenda or a counterweight to it. Heitsenrether's arrival does not resolve that question on its own.

The next proxy filing will show the full composition of the board after this wave of changes, and whether further seats shift before then will tell investors how settled the CVS governance picture actually is.

Mentioned: CVS